Page 62 - Read Online

Page 28 of 30 Raffetto et al. Vessel Plus 2021;5:36 https://dx.doi.org/10.20517/2574-1209.2021.16

secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-
controlled trial. Circulation 2015;132:1891-7. DOI PubMed PMC
182. Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther
2014;8:49-65. DOI PubMed PMC
183. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 2006;24:214-26. DOI
PubMed
184. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V. Randomised, double blind, multicentre, placebo controlled
study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002;87:947-52. PubMed
185. Scondotto G, Aloisi D, Ferrari P, Martini L. Treatment of venous leg ulcers with sulodexide. Angiology 1999;50:883-9. DOI
PubMed
186. Coccheri S. Biological and clinical effects of sulodexide in arterial disorders and diseases. Int Angiol 2014;33:263-74. PubMed
187. Andreozzi GM. Role of sulodexide in the treatment of CVD. Int Angiol 2014;33:255-62. PubMed
188. Liu YN, Zhou J, Li T, et al. Sulodexide protects renal tubular epithelial cells from oxidative stress-induced injury via upregulating
klotho expression at an early stage of diabetic kidney disease. J Diabetes Res 2017;2017:4989847. DOI PubMed PMC
189. Pletinck A, Van Landschoot M, Steppan S, et al. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of
peritoneal perfusion. Nephrol Dial Transplant 2012;27:548-56. DOI PubMed
190. Ligi D, Benitez S, Croce L, et al. Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation:
Inhibitory effect of glycosaminoglycan sulodexide. Biochim Biophys Acta Mol Basis Dis 2018;1864:3559-67. DOI PubMed
191. Ciszewicz M, Polubinska A, Antoniewicz A, Suminska-Jasinska K, Breborowicz A. Sulodexide suppresses inflammation in human
endothelial cells and prevents glucose cytotoxicity. Transl Res 2009;153:118-23. DOI PubMed
192. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev 1998;18:1-20.
DOI PubMed
193. Suminska-Jasinska K, Polubinska A, Ciszewicz M, Mikstacki A, Antoniewicz A, Breborowicz A. Sulodexide reduces senescence-
related changes in human endothelial cells. Med Sci Monit 2011;17:CR222-6. DOI PubMed PMC
194. Polubinska A, Staniszewski R, Baum E, Suminska-Jasinska K, Breborowicz A. Sulodexide modifies intravascular homeostasis what
affects function of the endothelium. Adv Med Sci 2013;58:304-10. DOI PubMed
195. Engberink RH, Heerspink HJ, de Zeeuw D, Vogt L. Blood pressure-lowering effects of sulodexide depend on albuminuria severity:
post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies. Br J Clin Pharmacol 2016;82:1351-7. DOI
PubMed PMC
196. Urbanek T, Zbigniew K, Begier-Krasinska B, Baum E, Breborowicz A. Sulodexide suppresses inflammation in patients with chronic
venous insufficiency. Int Angiol 2015;34:589-96. PubMed
197. Raffetto JD, Calanni F, Mattana P, Khalil RA. Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-
mediated pathway. Biochem Pharmacol 2019;166:347-56. DOI PubMed PMC
198. Engberink RH, Rorije NM, Lambers Heerspink HJ, De Zeeuw D, van den Born BJ, Vogt L. The blood pressure lowering potential of
sulodexide--a systematic review and meta-analysis. Br J Clin Pharmacol 2015;80:1245-53. DOI PubMed PMC
199. Bode W, Fernandez-Catalan C, Grams F, et al. Insights into MMP-TIMP interactions. Ann N Y Acad Sci 1999;878:73-91. DOI
PubMed
200. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73.
DOI PubMed
201. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci
2002;115:3719-27. DOI PubMed
202. Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue
inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem 2012;287:15935-46. DOI
PubMed PMC
203. Aravind B, Saunders B, Navin T, et al. Inhibitory effect of TIMP influences the morphology of varicose veins. Eur J Vasc Endovasc
Surg 2010;40:754-65. DOI PubMed
204. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, Jacob MP. Smooth muscle cell modulation and cytokine
overproduction in varicose veins. An in situ study. J Pathol 2001;193:398-407. DOI PubMed
205. Caimi G, Ferrara F, Montana M, et al. Behaviour of the plasma concentration of gelatinases and their tissue inhibitors in subjects with
venous leg ulcers. Clin Hemorheol Microcirc 2015;60:309-16. DOI PubMed
206. Li PC, Pan CH, Sheu MJ, Wu CC, Ma WF, Wu CH. Deep sea water prevents balloon angioplasty-induced hyperplasia through
MMP-2: an in vitro and in vivo study. PLoS One 2014;9:e96927. DOI PubMed PMC
207. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular
disease. Exp Suppl 2012;103:209-79. DOI PubMed PMC
208. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular
diseases. Nat Rev Drug Discov 2007;6:480-98. DOI PubMed
209. Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to
improved metalloproteinase inhibition. Biochim Biophys Acta 2010;1803:72-94. DOI PubMed
210. Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with
MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc
enzymes. J Med Chem 2000;43:3677-87. DOI PubMed